Indication: BRILINTA is superior to clopidogrel for at least the first 12 months following ACS2
BRILINTA is preferred over clopidogrel in ACS in the 2016 ACC/AHA DAPT guideline3
45,000 patients studied from a real-world registry confirmed the significant reductions in CV events for BRILINTA vs clopidogrel seen in the PLATO trial4,5
*Among P2Y12 inhibitors. Based on monthly market share performance in the STEMI PCI subsegment of ACS patient OAP initiation data for all hospitals within the IMS dataset, as of November 2016. Source: IMS: Charge Data Master (CDM) OAP Patient Data, November 2016.
Class of recommendation and level of evidence
BRILINTA is indicated to reduce the rate of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. For at least the first 12 months following ACS, it is superior to clopidogrel.
BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.
In the management of ACS, initiate BRILINTA treatment with a 180-mg loading dose. Administer 90 mg twice daily during the first year after an ACS event. After one year administer 60 mg twice daily. Use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg.